Company Overview and News

1
Singapore tycoons grew wealthier in 2018, new Forbes rich list reveals

2018-07-26 channelnewsasia - 1
SINGAPORE: The very rich in Singapore have grown wealthier, according to the 2018 Forbes Singapore Rich List.
5H0 DTK

1
Singapore's Decisive Property Crackdown Set to Damp `Euphoria'

2018-07-06 theedgemarkets - 1
(July 6): Singapore’s surprise crackdown to drive out speculative investments from the property market will probably hit collective sales that had become popular with developers of late, sending stocks reeling.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

 
Singapore’s decisive property crackdown set to damp ‘euphoria’

2018-07-06 thestar.com.my
SINGAPORE: Singapore’s surprise crackdown to drive out speculative investments from the property market will probably hit collective sales that had become popular with developers of late, sending stocks reeling. The tightened rules, rolled out a day after the central bank noted “euphoria” in the property market, sharply increase buyers’ stamp duties for entities such as developers. Singapore’s benchmark Straits Times Index dropped as much as 2.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

 
Singapore’s decisive property crackdown set to damp 'euphoria’

2018-07-06 malaymail
SINGAPORE, July 6 — Singapore’s surprise crackdown to drive out speculative investments from the property market will probably hit collective sales that had become popular with developers of late, sending stocks reeling.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

 
Singapore Developer Stocks Fall After Surprise Property Curbs

2018-07-06 theedgemarkets
(July 6): Singapore property and bank stocks led declines on the benchmark stock index Friday after the government unexpectedly tightened property curbs to cool a market the central bank described as euphoric. City Developments Ltd. and UOL Group Ltd. fell more than 14 percent each.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

10
OptimumBank Holdings, Inc. Strengthens Board of Directors with the Appointment of Mr. Heng Fai Ambrose Chan

2018-06-28 globenewswire
FORT LAUDERDALE, FL, June 28, 2018 (GLOBE NEWSWIRE) -- OptimumBank Holdings, Inc., the parent company of OptimumBank (www.OptimumBank.com) (NASDAQ: OPHC), a bank that provides a range of consumer and commercial banking services to individuals and businesses, is pleased to announce the appointment of Mr. Heng Fai Ambrose Chan (Mr. Chan) as a member to its Board of Directors. Mr. Chan is an accomplished business executive based in Singapore.
HCT SPXCY OPHC CGHLY SPXCF 5H0 RVSB RVSP CGHOF S68 0384

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...